Table 4.
TNM tumor stage | EGFR | Total | P value | |
---|---|---|---|---|
High | Low | |||
I + II | 0.000 | |||
N | 64 | 0 | 64 | |
% | 100.0% | 0.0% | 100.0% | |
III + IV | ||||
N | 5 | 45 | 50 | |
% | 10.0% | 90.0% | 100.0% | |
Total | ||||
N | 69 | 45 | 114 | |
% | 60.5% | 39.5% | 100.0% | |
| ||||
TNM tumor stage | VEGF | Total | P value | |
High | Low | |||
| ||||
I + II | 0.186 | |||
N | 27 | 37 | 64 | |
% | 42.2% | 57.8% | 100.0% | |
III + IV | ||||
N | 28 | 22 | 50 | |
% | 56.0% | 44.0% | 100.0% | |
Total | ||||
N | 55 | 59 | 114 | |
% | 48.2% | 51.8% | 100.0% | |
| ||||
TNM tumor stage | KI-67 | Total | P value | |
High | Low | |||
| ||||
I + II | 0.000 | |||
N | 38 | 26 | 64 | |
% | 59.4% | 40.6% | 100.0% | |
III + IV | ||||
N | 11 | 39 | 50 | |
% | 22.0% | 78.0% | 100.0% | |
Total | ||||
N | 49 | 65 | 114 | |
% | 43.0% | 57.0% | 100.0% | |
| ||||
Estadiamento | P53 | Total | P value | |
High | Low | |||
| ||||
I + II | 0.000 | |||
N | 35 | 29 | 64 | |
% | 54.7% | 45.3% | 100.0% | |
III + IV | ||||
N | 11 | 39 | 50 | |
% | 22.0% | 78.0% | 100.0% | |
Total | ||||
N | 46 | 68 | 114 | |
% | 40.4% | 59.6% | 100.0% | |
| ||||
TNM tumor stage | Bcl-2 | Total |
P value |
|
High | Low | |||
| ||||
I + II | 0.345 | |||
N | 29 | 35 | 64 | |
% | 45.3% | 54.7% | 100.0% | |
III + IV | ||||
N | 28 | 22 | 50 | |
% | 56.0% | 44.0% | 100.0% | |
Total | ||||
N | 57 | 57 | 114 | |
% | 50.0% | 50.0% | 100.0% | |
| ||||
TNM tumor stage | ITGB-5 | Total | P value | |
High | Low | |||
| ||||
I + II | 0.000 | |||
N | 49 | 15 | 64 | |
% | 76.6% | 23.4% | 100.0% | |
III + IV | ||||
N | 14 | 36 | 50 | |
% | 28.0% | 72.0% | 100.0% | |
Total | ||||
N | 63 | 51 | 114 | |
% | 55.3% | 44.7% | 100.0% | |
| ||||
TNM tumor stage | ITGA-3 | Total | P value | |
High | Low | |||
| ||||
I + II | 0.000 | |||
N | 53 | 11 | 64 | |
% | 82.8% | 17.2% | 100.0% | |
III + IV | ||||
N | 2 | 48 | 50 | |
% | 4.0% | 96.0% | 100.0% | |
Total | ||||
N | 55 | 59 | 114 | |
% | 48.2% | 51.8% | 100.0% | |
| ||||
TNM tumor stage | MMP-2 | Total | P value | |
High | Low | |||
| ||||
I + II | 0.572 | |||
N | 28 | 36 | 64 | |
% | 43.8% | 56.3% | 100.0% | |
III + IV | ||||
N | 25 | 25 | 50 | |
% | 50.0% | 50.0% | 100.0% | |
Total | ||||
N | 53 | 61 | 114 | |
% | 46.5% | 53.5% | 100.0% | |
| ||||
TNM tumor stage | MMP-9 | Total | P value | |
High | Low | |||
| ||||
I + II | 0.000 | |||
N | 56 | 8 | 64 | |
% | 87.5% | 12.5% | 100.0% | |
III + IV | ||||
N | 3 | 47 | 50 | |
% | 6.0% | 94.0% | 100.0% | |
Total | ||||
N | 59 | 55 | 114 | |
% | 51.8% | 48.2% | 100.0% | |
| ||||
TNM tumor stage | FN-1 | Total | P value | |
high | low | |||
| ||||
I + II | 0.677 | |||
N | 44 | 20 | 64 | |
% | 68.8% | 31.3% | 100.0% | |
III + IV | ||||
N | 37 | 13 | 50 | |
% | 74.0% | 26.0% | 100.0% | |
Total | ||||
N | 81 | 33 | 114 | |
% | 71.1% | 28.9% | 100.0% |